Skip to main content
GMAB logo

Genmab A/S

GMABNASDAQHealthcareBiotechnology

$37.82Today:- (-)1Y +15.48%

As of Oct 15, 2026 close

Market cap
$23.34B
P/E (TTM)
29.61
Forward P/E
36.72
Dividend yield
-
52-week range
$23.62$40.17
Volume (live)
-
Avg. volume (3M)
3.35M

Genmab A/S (GMAB) Key Statistics & Financial Metrics

Complete stock analysis with 60+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.

Stock Valuation Metrics

Market value, earnings multiples, and pricing ratios

Stock Price

Current price, 52-week range, and moving averages

Current Price$37.82
1-Day Change+2.52%
52-Week High$40.17
52-Week Low$23.62
YTD Change+18.86%
1-Year Change+15.48%
50-Day MA$34.00
200-Day MA$29.81
Avg Volume (30 day)3.35M

Analyst Price Targets & Consensus

Wall Street analyst ratings and 12-month price targets (90 days)

Price Target$112.22
Target Upside/Downside+196.72%
Analyst ConsensusBuy
Analyst Count11
View Analyst Forecast

Profitability & Financial Performance

Profit margins, return metrics, and earnings analysis

Growth Rates (YoY)

Year-over-year growth metrics

Revenue Growth+18.10%

Financial Health & Dividends

Balance sheet analysis, debt ratios, and dividend metrics

Fair Value & Intrinsic Value

Lynch fair value, Graham number, and valuation models

Graham Number$18.55
Graham Upside/Downside−50.96%

Source: Market prices and company fundamentals from financial filings. Data as of Oct 15, 2026. Data sources and methodology

Frequently Asked Questions About Genmab A/S Statistics

What are the key financial metrics for GMAB?

Genmab A/S (GMAB) statistics include 60+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.

What is GMAB's valuation analysis?

The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Genmab A/S is overvalued or undervalued.

How do I read GMAB's profitability ratios?

Genmab A/S's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.

What do GMAB's debt ratios indicate?

The financial health section shows Genmab A/S's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.

What is GMAB's dividend analysis?

The dividend section covers Genmab A/S's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.